- Home
- CLLS vs KVAC Comparison
CLLS vs KVAC Comparison
Compare CLLS & KVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- KVAC
- Stock Information
- Founded
- CLLS 1999
- KVAC 2021
- Country
- CLLS France
- KVAC United States
- Employees
- CLLS N/A
- KVAC N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- KVAC
- Sector
- CLLS Health Care
- KVAC
- Exchange
- CLLS Nasdaq
- KVAC Nasdaq
- Market Cap
- CLLS 148.1M
- KVAC 120.9M
- IPO Year
- CLLS 2007
- KVAC 2023
- Fundamental
- Price
- CLLS $1.45
- KVAC N/A
- Analyst Decision
- CLLS Buy
- KVAC
- Analyst Count
- CLLS 3
- KVAC 0
- Target Price
- CLLS $7.00
- KVAC N/A
- AVG Volume (30 Days)
- CLLS 120.5K
- KVAC 689.0
- Earning Date
- CLLS 05-27-2025
- KVAC 01-01-0001
- Dividend Yield
- CLLS N/A
- KVAC N/A
- EPS Growth
- CLLS N/A
- KVAC 197.31
- EPS
- CLLS N/A
- KVAC 0.41
- Revenue
- CLLS $49,217,000.00
- KVAC N/A
- Revenue This Year
- CLLS $1.26
- KVAC N/A
- Revenue Next Year
- CLLS N/A
- KVAC N/A
- P/E Ratio
- CLLS N/A
- KVAC $27.21
- Revenue Growth
- CLLS 435.38
- KVAC N/A
- 52 Week Low
- CLLS $1.10
- KVAC $10.47
- 52 Week High
- CLLS $3.38
- KVAC $11.25
- Technical
- Relative Strength Index (RSI)
- CLLS 60.38
- KVAC 72.19
- Support Level
- CLLS $1.40
- KVAC $11.20
- Resistance Level
- CLLS $1.56
- KVAC $11.14
- Average True Range (ATR)
- CLLS 0.09
- KVAC 0.00
- MACD
- CLLS 0.03
- KVAC 0.00
- Stochastic Oscillator
- CLLS 76.09
- KVAC 100.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About KVAC Keen Vision Acquisition Corporation
Keen Vision Acquisition Corp is a blank check company.